Entegris (ENTG) Q4 2025 earnings review
Stabilizing Near the Bottom; Efficiency Issues Persist
Entegris delivered a 'better-than-feared' Q4 under new CEO Dave Reeder, hitting the high end of guidance for revenue ($824M) and Non-GAAP EPS ($0.70). However, the YoY picture remains difficult: sales fell 3% and Adjusted EBITDA margin compressed 150bps to 27.7% as manufacturing underutilization weighed on profitability. While the company generated strong Free Cash Flow ($134M) to pay down debt, the operational story is mixed: Advanced Logic and AI are driving unit growth, but the CapEx-dependent APS segment continues to drag. Guidance for 26Q1 implies a return to YoY growth, signaling the cycle trough is likely passed.
🐂 Bull Case
Guidance for 26Q1 ($785-825M) implies ~4% YoY growth at the midpoint, marking a pivot from the contraction seen in late FY25. Inventory destocking appears largely complete.
Despite P&L pressure, Entegris generated $134M in Free Cash Flow in Q4 (up significantly from $69M in 24Q4). This fueled $150M in debt repayment, aligning with the new CEO's 'single priority' of deleveraging.
🐻 Bear Case
Adjusted Gross Margin fell to 44.0% (from 45.6% a year ago) and EBITDA margin dropped to 27.7%. Management cites underutilization of new facilities (Taiwan/Colorado), suggesting these expensive assets will remain a margin drag until volumes ramp significantly.
CEO Reeder explicitly stated the qualification process for the new Taiwan (KSP) facility is 'behind schedule.' With the localization strategy critical for Asian customers, further delays could jeopardize the FY26 recovery ramp.
⚖️ Verdict: ⚪
Neutral/Hold. Financials have stabilized and the guidance pivot to growth is a positive signal. However, the margin degradation from underutilized capacity and admitted delays at the KSP facility dampen the recovery thesis. We need to see volume leverage kick in before becoming constructive.
Key Themes
New Facility Ramp Issues
A major operational red flag: CEO Reeder admitted the Taiwan (KSP) facility qualification is 'behind schedule.' This adds risk to the localization strategy. Furthermore, the Colorado and Taiwan facilities are currently margin dilutive due to underutilization. The company is carrying the fixed costs of a $1B+ revenue capacity expansion without the sales volume to support it.
Liquid Filtration Strength
Liquid filtration achieved record quarterly sales in Q3 and remained a key driver in Q4. As node transitions (2nm/GAA) require higher purity, this product line is decoupling from the broader industry malaise, proving the 'content per wafer' growth thesis.
APS Segment Drag
Advanced Purity Solutions (APS) revenue fell 5.4% YoY. This segment is heavily tied to new fab construction (CapEx), which remains weak globally (down ~10%). Management describes the recovery in mainstream logic as 'muted' and 'slow,' limiting the upside for APS in H1 2026.
Aggressive Deleveraging
New leadership has defined debt reduction as the 'single priority' for capital allocation until gross leverage falls below 4.0x (currently ~4.3x). The company paid down $150M in debt in Q4. This discipline is welcome but effectively rules out M&A or buybacks in the near term.
AI & Advanced Node Demand
While mainstream markets are sluggish, Entegris confirmed strong demand in Advanced Logic and HBM driven by AI. Management noted 2x more plan-of-record (POR) wins for CMP slurries at the N2 node compared to N5, securing future revenue streams.
China Trade Uncertainty
Management continues to navigate a complex trade environment. While they aim to be >90% 'local-for-local' in China by 2026 to mitigate export bans, the 'wait-and-see' approach for the 2026 outlook suggests limited visibility on whether Chinese demand will sustain amidst geopolitical friction.
Other KPIs
Accelerating. Significant improvement from $68.6M in 24Q4. Management is prioritizing cash generation over inventory build, selectively lowering production to free up working capital.
Decelerating. Down from 29.2% in 24Q4. While improved sequentially from 25Q3 (27.3%), the year-over-year compression reflects the high fixed costs of unutilized capacity.
Stable. Still elevated above the <4.0x target, despite $150M repayment. Net debt stands at ~$3.5B.
Guidance
Reversing. The midpoint ($805M) implies +4.1% YoY growth vs 25Q1 ($773.2M), breaking the trend of YoY declines. Sequentially, it represents a seasonal dip from Q4 ($824M).
Accelerating. Midpoint ($0.74) represents ~10% growth vs 25Q1 ($0.67), suggesting that cost controls and mix shifts are starting to aid bottom-line recovery even before volume fully returns.
Decelerating. The guidance midpoint (27.0%) is lower than 25Q1 Actual (28.5%), indicating that fixed cost absorption from new facilities will continue to weigh on margins in early 2026.
Key Questions
KSP Delay Impact
You mentioned the Taiwan KSP facility is 'behind schedule.' What is the specific timeline for full qualification, and does this delay risk customer allocations in the competitive Asian market?
Margin Normalization
With EBITDA margins guiding down YoY in Q1 despite projected revenue growth, at what revenue run-rate do you expect to absorb the new facility costs and return to >29% margins?
APS Recovery Visibility
APS revenue remains negative YoY. Given the weak fab construction outlook (~10% decline mentioned), do you see this segment returning to growth in 2026, or will it remain a drag?